BACKGROUND: Indications for implantable cardioverter-defibrillators (ICDs) in heart failure (HF) are expanding and may include more than 1 million patients. This study examined patient expectations from ICDs for primary prevention of sudden death in HF. METHODS AND RESULTS: Study participants (n = 105) had an EF <35% and symptomatic HF, without history of ventricular tachycardia/fibrillation or syncope. Subjects completed a written survey about perceived ICD benefits, survival expectations, and circumstances under which they might deactivate defibrillation. Mean age was 58, LVEF 21%, 40% were New York Heart Association Class III-IV, and 65% already had a primary prevention ICD. Most patients anticipated more than10 years survival despite symptomatic HF. Nearly 54% expected an ICD to save >or=50 lives per 100 during 5 years. ICD recipients expressed more confidence that the device would save their own lives compared with those without an ICD (P < .001). Despite understanding the ease of deactivation, 70% of ICD recipients indicated they would keep the ICD on even if dying of cancer, 55% even if having daily shocks, and none would inactivate defibrillation even if suffering constant dyspnea at rest. CONCLUSIONS: HF patients anticipate long survival, overestimate survival benefits conferred by ICDs, and express reluctance to deactivate their devices even for end-stage disease. Copyright 2010 Elsevier Inc. All rights reserved.
BACKGROUND: Indications for implantable cardioverter-defibrillators (ICDs) in heart failure (HF) are expanding and may include more than 1 million patients. This study examined patient expectations from ICDs for primary prevention of sudden death in HF. METHODS AND RESULTS: Study participants (n = 105) had an EF <35% and symptomatic HF, without history of ventricular tachycardia/fibrillation or syncope. Subjects completed a written survey about perceived ICD benefits, survival expectations, and circumstances under which they might deactivate defibrillation. Mean age was 58, LVEF 21%, 40% were New York Heart Association Class III-IV, and 65% already had a primary prevention ICD. Most patients anticipated more than10 years survival despite symptomatic HF. Nearly 54% expected an ICD to save >or=50 lives per 100 during 5 years. ICD recipients expressed more confidence that the device would save their own lives compared with those without an ICD (P < .001). Despite understanding the ease of deactivation, 70% of ICD recipients indicated they would keep the ICD on even if dying of cancer, 55% even if having daily shocks, and none would inactivate defibrillation even if suffering constant dyspnea at rest. CONCLUSIONS: HF patients anticipate long survival, overestimate survival benefits conferred by ICDs, and express reluctance to deactivate their devices even for end-stage disease. Copyright 2010 Elsevier Inc. All rights reserved.
Authors: Ilan Goldenberg; Anant K Vyas; W Jackson Hall; Arthur J Moss; Hongyue Wang; Hua He; Wojciech Zareba; Scott McNitt; Mark L Andrews Journal: J Am Coll Cardiol Date: 2008-01-22 Impact factor: 24.094
Authors: Sue Ann Thomas; Erika Friedmann; Chi-Wen Kao; Pia Inguito; Matthew Metcalf; Frances J Kelley; Steven S Gottlieb Journal: Am J Crit Care Date: 2006-07 Impact factor: 2.228
Authors: Arthur J Moss; Henry Greenberg; Robert B Case; Wojciech Zareba; W Jackson Hall; Mary W Brown; James P Daubert; Scott McNitt; Mark L Andrews; Adam D Elkin Journal: Circulation Date: 2004-12-06 Impact factor: 29.690
Authors: James P Daubert; Wojciech Zareba; David S Cannom; Scott McNitt; Spencer Z Rosero; Paul Wang; Claudio Schuger; Jonathan S Steinberg; Steven L Higgins; David J Wilber; Helmut Klein; Mark L Andrews; W Jackson Hall; Arthur J Moss Journal: J Am Coll Cardiol Date: 2008-04-08 Impact factor: 24.094
Authors: Alan Kadish; Alan Dyer; James P Daubert; Rebecca Quigg; N A Mark Estes; Kelley P Anderson; Hugh Calkins; David Hoch; Jeffrey Goldberger; Alaa Shalaby; William E Sanders; Andi Schaechter; Joseph H Levine Journal: N Engl J Med Date: 2004-05-20 Impact factor: 91.245
Authors: Daniel B Kramer; Daniel D Matlock; Alfred E Buxton; Nathan E Goldstein; Carol Goodwin; Ariel R Green; James N Kirkpatrick; Christopher Knoepke; Rachel Lampert; Paul S Mueller; Matthew R Reynolds; John A Spertus; Lynne W Stevenson; Susan L Mitchell Journal: Circ Cardiovasc Qual Outcomes Date: 2015-06-02
Authors: Rachel A Hadler; Nathan E Goldstein; David B Bekelman; Barbara Riegel; Larry A Allen; Robert M Arnold; Matthew E Harinstein; Dio Kavalieratos Journal: J Cardiovasc Nurs Date: 2019 May/Jun Impact factor: 2.083
Authors: Ariel R Green; Amy Jenkins; Frederick A Masoudi; David J Magid; Jean S Kutner; Bruce Leff; Daniel D Matlock Journal: Pacing Clin Electrophysiol Date: 2016-09-22 Impact factor: 1.976
Authors: John A Dodson; Terri R Fried; Peter H Van Ness; Nathan E Goldstein; Rachel Lampert Journal: JAMA Intern Med Date: 2013-03-11 Impact factor: 21.873